Farms.com Home   News

PED On The Rise This Year In Manitoba

 
Hogs are being moved out of a finisher farm in southeast Manitoba, after the Porcine Epidemic Diarrhea (PED) Virus was discovered at the operation last week. The pigs are being moved out to the US market. The barn is being cleaned and disinfected and new pigs will be brought in once the disease is under control.
 
This was the tenth on-farm case of PED discovered in the province. The farm is within 5 km of a sow farm that was confirmed positive for PED on September 14th.
 
Manitoba Pork General Manager Andrew Dickson says they don't believe the two cases are directly related. Calls are currently being put out to find out where the disease might have come from and also where it might end up.
 
"The problem we've had with all the cases is that we've never been able to definitively say how each of those operations got the disease," commented Dickson. "There's so many potential ways the virus could be spread, by the time it got into a barn, the way it might have got in there is long past."
 
Dickson couldn't say how many pigs would be lost, but the number is in the hundreds. He notes the plan is to get both farms back into operation once the disease has been eradicated.
 
Source : Portageonline

Trending Video

New discovery may lead to better vaccines for pork producers

Video: New discovery may lead to better vaccines for pork producers



Porcine reproductive and respiratory syndrome virus (PRRSV) causes severe disease in pigs, leading to significant economic losses for pork producers across the globe. It’s estimated that PRRS costs the Canadian pork industry $130M annually. Using the CMCF beamline, researchers from the University of Manitoba and the Leiden University Medical Centre (Netherlands) were able to see the structure of the PRRSV protease, a type of protein the pathogen uses to suppress a host’s immune system. The vital information they uncovered can be used to develop new vaccines against PRRSV and also helps inform development of vaccines against emerging human viruses.